Clinical Syndrome
Conditions
Brief summary
Chikungunya viral infection (CVI) is a mosquito-borne infection, caused by chikungunya virus (CHIKV), an alphavirus, belonging to the family Togaviridae. This infection causes febrile illness associated with high fever, rash, acute deliberating and persistent arthralgia. There is no licensed vaccine or specific treatment for this infection. Ivermectin (IVM), commonly-used antiparasitic, has been demonstrated to inhibit replication of CHIKV.
Interventions
DRUGIvermectin
3-day 1 daily dose of 400 μg/kg oral ivermectin
Sponsors
Prince of Songkla University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* patients with virologic confirmation of chikungunya infection who had symptoms less than 72 hours prior to visit
Exclusion criteria
* patients with virologic confirmation of chikungunya infection who had symptoms more than 72 hours prior to visit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Day of fever clearance | 1 week | 120 participants would be under Body Temperature Assessment - the staff would assess once daily until the fever clearance was below 38C and the measure proportion of patients with fever clearance in each day of assessment until fever clearance at least in 7 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Day of virologic clearance | 1 week | 120 participants would be obtained blood examination for virological testing every day until virological clearance at least in 7 days |
Countries
Thailand
Outcome results
None listed